FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular, to an application of epidermal growth factor (EGF) and GHRP6 peptide enhancing the secretion of growth hormone for producing a pharmaceutical combination for restoring brain damage after cerebral infarction or brain hypoxia. Said combination includes 0.3 to 0.9 mcg EGF per kg of body weight and 30 to 80 mcg GHRP6 per kg of body weight.
EFFECT: invention is effective in restoring brain damage after cerebral infarction or brain hypoxia.
6 cl, 7 dwg, 1 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
COMPOSITIONS AND METHODS FOR TREATMENT DURING NON-ACUTE PERIODS FOLLOWING NEUROLOGICAL CNS DAMAGE | 2013 |
|
RU2646507C2 |
COMPOSITIONS AND METHODS FOR TREATING NON-ACUTE PERIODS FOLLOWING NEUROLOGICAL DAMAGE | 2009 |
|
RU2501564C2 |
COMPOUNDS AND PHARMACEUTIC COMBINATIONS FOR TREATMENT OF NEURODEGENERATIVE AND ISCHEMIC BRAIN DISEASES | 2012 |
|
RU2569302C2 |
METHOD OF PERSONALIZED GENE THERAPY IN CASE THERE IS THREAT OF ISCHEMIC CEREBRAL STROKE | 2023 |
|
RU2808256C1 |
COMBINED THERAPY FOR PATIENTS WITH NEUROLOGICAL DISORDERS AND CEREBRAL INFARCTION | 2007 |
|
RU2486914C2 |
METHOD OF INHALATION SEDATION IN SEVERE ISCHEMIC STROKE | 2022 |
|
RU2797218C1 |
METHOD OF TREATING ACUTE ISCHEMIC AND HEMORRHAGIC CEREBROVASCULAR DISEASE | 2010 |
|
RU2477637C2 |
METHOD AND IMPROVED NEUROPROTECTIVE COMPOSITION FOR TREATMENT OF NEUROLOGICAL PATHOLOGICAL CONDITIONS | 2018 |
|
RU2758376C2 |
METHOD FOR TREATMENT OF ISCHEMIC STROKE | 2018 |
|
RU2670203C1 |
EGF/GHRP-6 COMBINATION FOR CENTRAL NERVOUS SYSTEM NEUROREGENERATION AFTER AUTOIMMUNNE DAMAGE | 2006 |
|
RU2403913C2 |
Authors
Dates
2022-07-26—Published
2019-08-16—Filed